|
|
|||||||||||||||||||
|
|||||||||||||||||||
Introducing EpidymeEpidyme is a pharmaceutical research company developing commercial products in the field of immuno-therapy.Immune processes are vital as a defence against the disease organisms with which we are constantly confronted in our environment. However, the immune system can itself be responsible for diseases, either where it overreacts to a harmless environmental stimulus (for example hay fever) or where it mistakenly attacks natural components of the body (autoimmune disease). Epidyme's approach is based on a method of modulating the response of the immune system to specific antigens. We believe that this can target the specific immune response implicated in a disease process. The company is concentrating its efforts on autoimmune diseases. Our lead development prospect is a treatment for rheumatoid arthritis, which is estimated to affect 20 million people worldwide and accounted for over $7bn of pharmaceutical industry sales in 2004. However, the field of autoimmune disease includes many other significant conditions which may benefit from the application of our technology. Recent web site updatesOther links |